Cargando…

PO-1174 3-weekly paclitaxel-carboplatin with radiation for stage III NSCLC – option during COVID-19 pandemic

Detalles Bibliográficos
Autores principales:	Wong, H., Lim, F., Cheng, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ireland Ltd. 2021
Materias:	Digital Poster: Lung
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629141/ http://dx.doi.org/10.1016/S0167-8140(21)07625-8

Ejemplares similares

3-Weekly Paclitaxel-Carboplatin With Radical Radiation for Stage III NSCLC – An Option During COVID-19 Pandemic
por: Wong, H.C.Y., et al.
Publicado: (2021)

PO-1165 Dosimetric parameters in hypofractionated radiotherapy in NSCLC cohort during SARS-COV-2 pandemia
por: González Ruiz, M.A., et al.
Publicado: (2021)

PO-1181 Hypofractionation in NSCLC as the new standard of care during SARS-CoV-2 pandemia.
por: Vera Barragán, V., et al.
Publicado: (2021)

PO-1179 Radiation induced pneumonitis during COVID-19: artificial intelligence for differential diagnosis.
por: Ippolito, E., et al.
Publicado: (2021)

PO-1249 The impact of COVID-19 pandemic in the lung cancer treatment in a radiotherapy service
por: Costa, S., et al.
Publicado: (2022)

PO-1198 Changes in radical radiotherapy for lung cancer patients in the UK during the COVID-19 pandemic.
por: croxford, W., et al.
Publicado: (2021)

PO-1524 On how COVID-19 has affected radiation therapy treatments
por: Ambroa Rey, E.M., et al.
Publicado: (2021)

PO-1060 Survival Analysis for Whole Lung Radiation in Patients with Acute Respiratory Syndrome for COVID-19
por: Ortiz Arce, C.S., et al.
Publicado: (2022)

PO-1484 Impact of COVID-19 pandemic on Radiation Oncology practice. An overview of recent higher quality reports
por: Carbonara, R., et al.
Publicado: (2021)

A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer
por: Marrone, Kristen A., et al.
Publicado: (2018)

PO-1561 Low Dose Radiation Therapy for COVID-19 Pneumonia: Risk of Cancer with AP-PA fields and IMRT
por: Sharma, D.N., et al.
Publicado: (2022)

PO-1480 Implementation of a self-administered patient health history questionnaire in a radiation oncology department during COVID-19.
por: Houlihan, O., et al.
Publicado: (2021)

PO-1059 The contribution of hypofractionated radiotherapy during the COVID 19 pandemic
por: Dhouib, F., et al.
Publicado: (2022)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

PO-1514 Prospective assessment of employees stress during the COVID-19 pandemic
por: Guckenberger, M., et al.
Publicado: (2021)

PO-1517 Which impact of the COVID-19 pandemic on residents training in radiotherapy?
por: Fourati, N., et al.
Publicado: (2021)

PO-1476 Covid-19 era and radiotherapy: psychological changes in oncological patients
por: Caliandro, M., et al.
Publicado: (2021)

PO-1453 Psychological impact of COVID-19 to patients undergoing radiation therapy
por: Oualha, A., et al.
Publicado: (2022)

PO-1420 iCARE: sarcoma patient radiotherapy experience during COVID-19
por: McCabe, H., et al.
Publicado: (2021)

PO-1494 Universal testing for SARS-Cov-2 in patients undergoing anticancer treatment.
por: Guerini, A.E., et al.
Publicado: (2021)

PO-1058 Estimating the carbon footprint of the radiotherapy pathway and changes in response to COVID-19
por: Cummings, J., et al.
Publicado: (2022)

Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial)
por: Taylor, Sally, et al.
Publicado: (2021)

PO-1528 Mood disorder in cancer patients undergoing radiotherapy during the COVID-19 outbreak
por: Nardone, V., et al.
Publicado: (2021)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
por: Katsurada, Naoko, et al.
Publicado: (2020)

Cellular Therapy in NSCLC: Between Myth and Reality
por: Imbimbo, Martina, et al.
Publicado: (2023)

PO-1100 Implementation of FAST-Forward during COVID19: Report of acute skin toxicity /resource implications
por: Nugent, K., et al.
Publicado: (2021)

PO-1505 Phone call triage for patients admission in a radiotherapy department during COVID 19 pandemic
por: Santo, B., et al.
Publicado: (2021)

PO-1506 Psychological impact of COVID 19 pandemic in cancer patients: a cross sectional observational study
por: SANTO, B., et al.
Publicado: (2021)

PO-1070 Impact of COVID-19 in cancer patients: Analysis of the first 20 months in 13 Spanish Centers
por: Romero, S., et al.
Publicado: (2022)

PO-1327 Prostate cancer radiotherapy in a COVID-19 pandemic year: experience of a chilean public hospital
por: Letelier, H., et al.
Publicado: (2021)

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
por: Thomas, Michael, et al.
Publicado: (2017)

Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)
por: Lapointe, Réjean, et al.
Publicado: (2015)

Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer
por: Yumuk, Perran F, et al.
Publicado: (2005)

PO-1464 Impact of COVID-19 on Radiation Oncology, an Austrian Experience
por: Mangesius, J., et al.
Publicado: (2021)

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
por: Yamada, Tadaaki, et al.
Publicado: (2020)

PO-1461 Impact of the COVID-19 pandemic on Radiation Oncology Departments in Brazil
por: Yoshinari Jr, G.H., et al.
Publicado: (2021)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis
por: Woodford, Katrina, et al.
Publicado: (2022)

Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
por: Geraghty, Leeann, et al.
Publicado: (2021)

Voxel-Level BED Corrected Dosimetric and Radiobiological Assessment of 2 Kinds of Hybrid Radiotherapy Planning Methods for Stage III NSCLC
por: Wang, Hao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jbh0c6c3gfef2e66v0s19na806